Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush

Wedbush restated their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a research report released on Friday,Benzinga reports. Wedbush currently has a $15.00 price target on the stock.

Other research analysts have also issued research reports about the company. HC Wainwright cut their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Scotiabank cut their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Finally, Truist Financial lowered their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Trading Up 3.3%

Shares of NASDAQ KROS traded up $0.49 during mid-day trading on Friday, reaching $15.15. The company had a trading volume of 251,458 shares, compared to its average volume of 844,105. The firm has a 50 day simple moving average of $13.07 and a two-hundred day simple moving average of $18.85. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37. The stock has a market cap of $615.32 million, a P/E ratio of -2.91 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the prior year, the firm posted ($1.21) earnings per share. On average, equities analysts expect that Keros Therapeutics will post -4.74 EPS for the current year.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.60% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the period. SG Americas Securities LLC purchased a new stake in Keros Therapeutics during the fourth quarter worth about $388,000. Exchange Traded Concepts LLC acquired a new position in Keros Therapeutics during the fourth quarter worth about $99,000. China Universal Asset Management Co. Ltd. grew its position in Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after buying an additional 1,372 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after buying an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.